Target intelligence / Profile preview

ARHGEF35 antisense RNA 1 (ARHGEF35-AS1)

Target
ARHGEF35-AS1
Molecular classification
Long non-coding RNA, Natural antisense transcript, Regulatory RNA
01

Overview

ARHGEF35 antisense RNA 1 (ARHGEF35-AS1, also called DDGC) is a long non-coding antisense RNA implicated in the regulation of DNA repair and differentiation within ovarian granulosa cells. It exerts its effect by stabilizing RAD51 messenger RNA—critical for homologous recombination DNA repair—through competition for miR-589-5p binding, functioning as a competitive endogenous RNA (ceRNA). Additionally, DDGC modulates granulosa cell differentiation by facilitating interaction between the chaperone protein HSP90 and the transcription factor WT1, thereby protecting WT1 from ubiquitin-mediated degradation and allowing proper cell differentiation and hormone production. Aberrant expression or silencing of ARHGEF35-AS1 leads to decreased DNA repair capacity, abnormal cell differentiation, and has been linked to premature ovarian insufficiency. To date, there are no drugs or diagnostic agents targeting ARHGEF35-AS1.

Other names
DDGCDNA damage repair and differentiation of GC regulatory RNARP4-545C24.1ARHGEF35-AS1
02

Mechanism of action

Not applicable (no direct drug interactions). Endogenously, ARHGEF35-AS1: Acts as a microRNA sponge for miR-589-5p, stabilizing RAD51 mRNA and modulating DNA repair.

03

Biological functions

DNA damage repairRegulation of granulosa cell (GC) differentiationModulation of gene expression
04

Disease associations

Premature ovarian insufficiency (POI)Potential involvement in disorders of ovarian function and fertility
05

Safety considerations

None reported
06

Interacting drugs

None
07

Biomarkers

None currently validated

Beyond the preview

Go deeper on ARHGEF35 antisense RNA 1 (ARHGEF35-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARHGEF35 antisense RNA 1 (ARHGEF35-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call